masteron 100

In patients masteron 100 with impaired liver mild to moderate function (class A and B in Child-Pugh).
Patients with an allergy to sulfonamides.

Application of pregnancy and during breastfeeding

High-grade studies of darunavir in pregnant women have been conducted. Animal studies have revealed no toxic activity of darunavir or negative impact on reproductive function and fertility.

The combination of drugs ritonavir can be used during pregnancy only if the expected benefit of its application for future mother outweighs the potential risk to the fetus.

It is not known whether darunavir is able to penetrate into breast milk. Studies in rats have shown that the drug penetrates the milk. Given the possibility of HIV transmission through breast milk, as well as the risk of serious side effects in infants, linked to exposure to darunavir, HIV-infected women receiving the drug Prezista ® , should refrain from breastfeeding.

Dosing and Administration

Inside. Preparation masteron 100should always be given in combination with low dose ritonavir as a means of improving its pharmacokinetic properties, as well as in combination with other antiretroviral drugs.The ability to assign ritonavir should be considered prior to initiating therapy combination ritonavir.

Patients should be instructed on the admission of the with low-dose ritonavir within 30 minutes after the meal is finished.

After the start of therapy with  patients do not need to modify or discontinue therapy without consulting with their physician.

Rash

In clinical trials, rash was observed mainly mild or moderate. The rash appears most often during the first four weeks of treatment and disappear with continued dosing. With the development of skin reactions, severe see. “Special Instructions” section.

In clinical studies in patients who have received prior therapy, rash, regardless of the cause, more often occurred when receiving regimens containing the masteron 100and raltegravir than when taking the drug Prezista ® without raltegravir or raltegravir without . The rash caused by drug intake, appeared with a similar frequency. Arises in clinical trials rash was mild to moderate and did not lead to discontinuation of therapy.

Lipodystrophy

Combination antiretroviral therapy causes a redistribution of body fat (lipodystrophy) in HIV patients. Lipodystrophy was manifested in the form of the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and accumulation of fat dorsotservikalnogo ( “buffalo hump”).

Violations of the metabolism

Combination antiretroviral therapy causes metabolic disorders such as hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia and hyperlactatemia.